High-Grade Gliomas

Diagnosis and Treatment

  • Gene H. Barnett

Part of the Current Clinical Oncology book series (CCO)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Classification of High-Grade Glioma

    1. Front Matter
      Pages 1-1
    2. Richard A. Prayson
      Pages 3-35
    3. Gregory N. Fuller
      Pages 37-42
  3. Clinical Characteristics

    1. Front Matter
      Pages 43-43
    2. Bruce H. Cohen
      Pages 45-58
    3. Nicholas Butowski, Susan Chang
      Pages 59-69
  4. Diagnostic Tools for High-Grade Glioma

    1. Front Matter
      Pages 71-71
    2. Manzoor Ahmed, Thomas J. Masaryk
      Pages 73-104
    3. Paul M. Ruggieri
      Pages 105-132
    4. G. Evren Keles, Soonmee Cha, Mitchel S. Berger
      Pages 133-140
    5. Timothy P. L. Roberts, Andrea Kassner
      Pages 141-159
    6. Alexander M. Spence, David A. Mankoff, Mark Muzi, Kristin Swanson
      Pages 161-186
    7. Michael P. Steinmetz, Jürgen Lüders, Edward C. Benzel
      Pages 187-195
  5. Management

    1. Front Matter
      Pages 197-197
    2. Glen H. J. Stevens
      Pages 199-211
    3. Gene H. Barnett
      Pages 213-230
    4. Hiral K. Shah, Minesh P. Mehta
      Pages 231-244
    5. Marcus L. Ware, P. K. Sneed, Michael W. McDermott
      Pages 245-256
    6. John H. Suh, Gene H. Barnett
      Pages 257-266

About this book


This is truly an exciting time in the field of neuro-oncology, particularly in the area of hi- grade gliomas. The management of patients with high-grade gliomas has historically been one of the most challenging and disheartening fields in medicine, where failure is the rule and longevity is the exception. The jaded often state that despite purported advances in surgical and radiotherapeutic techniques and a myriad of clinical trials of medical therapies, the s- vival statistics for glioblastoma have not changed in the last three decades. The nihilism associated with these tumors is such that some practitioners still advise against treatment or even biopsy, recommending palliative care with the diagnosis based only on history and an MRI scan. If the current state-of-the-art in the diagnosis and management of high-grade gliomas was truly so bleak, there would be no reason to compile and publish a monograph on the subject. The fact is that we have recently entered an era where real progress is being made in our understanding and treatment of high-grade gliomas that is directly benefiting some patients. We are slowly but surely chipping away at this problem. One approach has exploited correlations between particular molecular markers and therapeutic response. The first such “breakthrough” in high-grade glioma was the observation that loss of chromosomes 1p and 19q uniformly predict chemosensitivity in anaplastic oligodendrogliomas (1).


Chemotherapie brachytherapy classification glioma imaging techniques radiosurgery surgery

Editors and affiliations

  • Gene H. Barnett
    • 1
  1. 1.Department of Neurological Surgery Cleveland Clinic FoundationBrain Tumor InstituteCleveland

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-59745-185-7
  • Copyright Information Humana Press Inc. 2007
  • Publisher Name Humana Press
  • eBook Packages Medicine
  • Print ISBN 978-1-58829-511-8
  • Online ISBN 978-1-59745-185-7
  • About this book